Listed

Northwest Biotherapeutics Inc

NWBOOTCCIK 1072379HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$807.0k, Q2 FY2026
Operating income−$11.6m, Q2 FY2026
Net income−$9.2m, Q2 FY2026
Northwest Biotherapeutics Inc, income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.4Revenue, Q3 FY2023, three months to 2023-09-30$406.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-12, accession 0001410578-24-001879.Report this figure0.4Revenue, Q4 FY2023, three months to 2023-12-31$445.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-31, accession 0001410578-25-000598. Derived: 12-month figure less the 9-month figure.Report this figure0.3Revenue, Q1 FY2024, three months to 2024-03-31$284.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-15, accession 0001410578-25-001333.Report this figure0.5Revenue, Q2 FY2024, three months to 2024-06-30$510.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-14, accession 0001410578-25-001825.Report this figure0.4Revenue, Q3 FY2024, three months to 2024-09-30$357.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure0.2Revenue, Q4 FY2024, three months to 2024-12-31$231.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure0.4Revenue, Q1 FY2025, three months to 2025-03-31$375.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure0.1Revenue, Q2 FY2025, three months to 2025-06-30$131.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure0.2Revenue, Q3 FY2025, three months to 2025-09-30$200.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure0.7Revenue, Q4 FY2025, three months to 2025-12-31$672.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure0.5Revenue, Q1 FY2026, three months to 2026-03-31$494.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure0.8Revenue, Q2 FY2026, three months to 2026-06-30$807.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure
Cost of revenue$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$m7.2Research and development, Q3 FY2023, three months to 2023-09-30$7.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0001410578-24-001879.Report this figure7.5Research and development, Q4 FY2023, three months to 2023-12-31$7.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-31, accession 0001410578-25-000598. Derived: 12-month figure less the 9-month figure.Report this figure7.9Research and development, Q1 FY2024, three months to 2024-03-31$7.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-15, accession 0001410578-25-001333.Report this figure8.3Research and development, Q2 FY2024, three months to 2024-06-30$8.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-14, accession 0001410578-25-001825.Report this figure8.1Research and development, Q3 FY2024, three months to 2024-09-30$8.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure10.5Research and development, Q4 FY2024, three months to 2024-12-31$10.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure8.4Research and development, Q1 FY2025, three months to 2025-03-31$8.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure7.4Research and development, Q2 FY2025, three months to 2025-06-30$7.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure7.5Research and development, Q3 FY2025, three months to 2025-09-30$7.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure5.6Research and development, Q4 FY2025, three months to 2025-12-31$5.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure4.9Research and development, Q1 FY2026, three months to 2026-03-31$4.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure5.7Research and development, Q2 FY2026, three months to 2026-06-30$5.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure
Operating income$m(13.8)Operating income, Q3 FY2023, three months to 2023-09-30−$13.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0001410578-24-001879.Report this figure(15.1)Operating income, Q4 FY2023, three months to 2023-12-31−$15.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-31, accession 0001410578-25-000598. Derived: 12-month figure less the 9-month figure.Report this figure(15.7)Operating income, Q1 FY2024, three months to 2024-03-31−$15.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-15, accession 0001410578-25-001333.Report this figure(17.5)Operating income, Q2 FY2024, three months to 2024-06-30−$17.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-14, accession 0001410578-25-001825.Report this figure(14.8)Operating income, Q3 FY2024, three months to 2024-09-30−$14.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure(18.5)Operating income, Q4 FY2024, three months to 2024-12-31−$18.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure(17.3)Operating income, Q1 FY2025, three months to 2025-03-31−$17.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure(14.8)Operating income, Q2 FY2025, three months to 2025-06-30−$14.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure(14.3)Operating income, Q3 FY2025, three months to 2025-09-30−$14.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure(13.5)Operating income, Q4 FY2025, three months to 2025-12-31−$13.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure(10.9)Operating income, Q1 FY2026, three months to 2026-03-31−$10.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure(11.6)Operating income, Q2 FY2026, three months to 2026-06-30−$11.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure
Interest expense$m1.7Interest expense, Q3 FY2023, three months to 2023-09-30$1.7m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2023-11-09, accession 0001410578-23-002304.Report this figure1.2Interest expense, Q4 FY2023, three months to 2023-12-31$1.2m. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-03-05, accession 0001410578-24-000133. Derived: 12-month figure less the 9-month figure.Report this figure1.5Interest expense, Q1 FY2024, three months to 2024-03-31$1.5m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-10, accession 0001410578-24-000741.Report this figure1.7Interest expense, Q2 FY2024, three months to 2024-06-30$1.7m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-14, accession 0001410578-25-001825.Report this figure2.1Interest expense, Q3 FY2024, three months to 2024-09-30$2.1m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure2.5Interest expense, Q4 FY2024, three months to 2024-12-31$2.5m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure1.6Interest expense, Q1 FY2025, three months to 2025-03-31$1.6m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure1.8Interest expense, Q2 FY2025, three months to 2025-06-30$1.8m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure2.6Interest expense, Q3 FY2025, three months to 2025-09-30$2.6m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure2.6Interest expense, Q4 FY2025, three months to 2025-12-31$2.6m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure2.3Interest expense, Q1 FY2026, three months to 2026-03-31$2.3m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure1.8Interest expense, Q2 FY2026, three months to 2026-06-30$1.8m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure
Net income$m(23.5)Net income, Q3 FY2023, three months to 2023-09-30−$23.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-12, accession 0001410578-24-001879.Report this figure(14.0)Net income, Q4 FY2023, three months to 2023-12-31−$14.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-31, accession 0001410578-25-000598. Derived: 12-month figure less the 9-month figure.Report this figure(18.3)Net income, Q1 FY2024, three months to 2024-03-31−$18.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-15, accession 0001410578-25-001333.Report this figure(17.9)Net income, Q2 FY2024, three months to 2024-06-30−$17.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-14, accession 0001410578-25-001825.Report this figure(19.4)Net income, Q3 FY2024, three months to 2024-09-30−$19.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure(28.2)Net income, Q4 FY2024, three months to 2024-12-31−$28.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure(19.3)Net income, Q1 FY2025, three months to 2025-03-31−$19.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure(15.4)Net income, Q2 FY2025, three months to 2025-06-30−$15.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure(26.8)Net income, Q3 FY2025, three months to 2025-09-30−$26.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure1.4Net income, Q4 FY2025, three months to 2025-12-31$1.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure(3.1)Net income, Q1 FY2026, three months to 2026-03-31−$3.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure(9.2)Net income, Q2 FY2026, three months to 2026-06-30−$9.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure
Diluted EPS$ per share(0.02)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0001410578-24-001879.Report this figurenot reported(0.02)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-15, accession 0001410578-25-001333.Report this figure(0.02)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-14, accession 0001410578-25-001825.Report this figure(0.02)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figurenot reported(0.01)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure(0.01)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure(0.02)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figurenot reported0.00Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure(0.01)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure
Basic EPS$ per share(0.02)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0001410578-24-001879.Report this figurenot reported(0.02)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-15, accession 0001410578-25-001333.Report this figure(0.02)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-14, accession 0001410578-25-001825.Report this figure(0.02)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figurenot reported(0.01)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure(0.01)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure(0.02)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figurenot reported0.00Basic EPS, Q1 FY2026, three months to 2026-03-31$0.00 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure(0.01)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure

Balance sheet

Cash and equivalents$595.0k, Q2 FY2026
Long-term debt$52.0m, Q2 FY2026
Shareholders' equity−$45.2m, Q2 FY2026
Northwest Biotherapeutics Inc, balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m6.1Cash and equivalents, Q3 FY2023, at 2023-09-30$6.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-09, accession 0001410578-23-002304.Report this figure2.1Cash and equivalents, FY2023, at 2023-12-31$2.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-31, accession 0001410578-25-000598.Report this figure2.5Cash and equivalents, Q1 FY2024, at 2024-03-31$2.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-10, accession 0001410578-24-000741.Report this figure2.9Cash and equivalents, Q2 FY2024, at 2024-06-30$2.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-09, accession 0001410578-24-001278.Report this figure2.9Cash and equivalents, Q3 FY2024, at 2024-09-30$2.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0001410578-24-001879.Report this figure2.2Cash and equivalents, FY2024, at 2024-12-31$2.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-04-15, accession 0001104659-26-043806.Report this figure2.8Cash and equivalents, Q1 FY2025, at 2025-03-31$2.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-15, accession 0001410578-25-001333.Report this figure4.3Cash and equivalents, Q2 FY2025, at 2025-06-30$4.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-14, accession 0001410578-25-001825.Report this figure4.6Cash and equivalents, Q3 FY2025, at 2025-09-30$4.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure3.0Cash and equivalents, FY2025, at 2025-12-31$3.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure1.8Cash and equivalents, Q1 FY2026, at 2026-03-31$1.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure0.6Cash and equivalents, Q2 FY2026, at 2026-06-30$595.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure
Current assets$m8.5Current assets, Q3 FY2023, at 2023-09-30$8.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0001410578-23-002304.Report this figure4.1Current assets, FY2023, at 2023-12-31$4.1m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-31, accession 0001410578-25-000598.Report this figure4.9Current assets, Q1 FY2024, at 2024-03-31$4.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-10, accession 0001410578-24-000741.Report this figure5.0Current assets, Q2 FY2024, at 2024-06-30$5.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-09, accession 0001410578-24-001278.Report this figure5.2Current assets, Q3 FY2024, at 2024-09-30$5.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0001410578-24-001879.Report this figure4.1Current assets, FY2024, at 2024-12-31$4.1m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-04-15, accession 0001104659-26-043806.Report this figure4.7Current assets, Q1 FY2025, at 2025-03-31$4.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-15, accession 0001410578-25-001333.Report this figure6.2Current assets, Q2 FY2025, at 2025-06-30$6.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-14, accession 0001410578-25-001825.Report this figure7.2Current assets, Q3 FY2025, at 2025-09-30$7.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure5.5Current assets, FY2025, at 2025-12-31$5.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure6.2Current assets, Q1 FY2026, at 2026-03-31$6.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure2.6Current assets, Q2 FY2026, at 2026-06-30$2.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure
Total assets$m31.5Total assets, Q3 FY2023, at 2023-09-30$31.5m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0001410578-23-002304.Report this figure27.9Total assets, FY2023, at 2023-12-31$27.9m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-31, accession 0001410578-25-000598.Report this figure28.6Total assets, Q1 FY2024, at 2024-03-31$28.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-10, accession 0001410578-24-000741.Report this figure28.2Total assets, Q2 FY2024, at 2024-06-30$28.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-09, accession 0001410578-24-001278.Report this figure29.3Total assets, Q3 FY2024, at 2024-09-30$29.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0001410578-24-001879.Report this figure26.7Total assets, FY2024, at 2024-12-31$26.7m. XBRL concept us-gaap:Assets. 10-K filed 2026-04-15, accession 0001104659-26-043806.Report this figure27.5Total assets, Q1 FY2025, at 2025-03-31$27.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-15, accession 0001410578-25-001333.Report this figure29.5Total assets, Q2 FY2025, at 2025-06-30$29.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-14, accession 0001410578-25-001825.Report this figure30.6Total assets, Q3 FY2025, at 2025-09-30$30.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure81.3Total assets, FY2025, at 2025-12-31$81.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure80.1Total assets, Q1 FY2026, at 2026-03-31$80.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure75.9Total assets, Q2 FY2026, at 2026-06-30$75.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure
Current liabilities$m49.2Current liabilities, Q3 FY2023, at 2023-09-30$49.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0001410578-23-002304.Report this figure45.2Current liabilities, FY2023, at 2023-12-31$45.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-31, accession 0001410578-25-000598.Report this figure62.4Current liabilities, Q1 FY2024, at 2024-03-31$62.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-10, accession 0001410578-24-000741.Report this figure56.2Current liabilities, Q2 FY2024, at 2024-06-30$56.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-09, accession 0001410578-24-001278.Report this figure59.6Current liabilities, Q3 FY2024, at 2024-09-30$59.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0001410578-24-001879.Report this figure68.3Current liabilities, FY2024, at 2024-12-31$68.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-04-15, accession 0001104659-26-043806.Report this figure83.1Current liabilities, Q1 FY2025, at 2025-03-31$83.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-15, accession 0001410578-25-001333.Report this figure83.9Current liabilities, Q2 FY2025, at 2025-06-30$83.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-14, accession 0001410578-25-001825.Report this figure87.9Current liabilities, Q3 FY2025, at 2025-09-30$87.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure91.7Current liabilities, FY2025, at 2025-12-31$91.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure83.0Current liabilities, Q1 FY2026, at 2026-03-31$83.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure73.4Current liabilities, Q2 FY2026, at 2026-06-30$73.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure
Total liabilities$m68.9Total liabilities, Q3 FY2023, at 2023-09-30$68.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0001410578-23-002304.Report this figure74.9Total liabilities, FY2023, at 2023-12-31$74.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-31, accession 0001410578-25-000598.Report this figure82.0Total liabilities, Q1 FY2024, at 2024-03-31$82.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-10, accession 0001410578-24-000741.Report this figure86.0Total liabilities, Q2 FY2024, at 2024-06-30$86.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-09, accession 0001410578-24-001278.Report this figure93.6Total liabilities, Q3 FY2024, at 2024-09-30$93.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0001410578-24-001879.Report this figure106Total liabilities, FY2024, at 2024-12-31$105.7m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-04-15, accession 0001104659-26-043806.Report this figure112Total liabilities, Q1 FY2025, at 2025-03-31$112.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-15, accession 0001410578-25-001333.Report this figure116Total liabilities, Q2 FY2025, at 2025-06-30$116.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-14, accession 0001410578-25-001825.Report this figure126Total liabilities, Q3 FY2025, at 2025-09-30$125.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure129Total liabilities, FY2025, at 2025-12-31$128.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure118Total liabilities, Q1 FY2026, at 2026-03-31$118.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure111Total liabilities, Q2 FY2026, at 2026-06-30$110.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure
Long-term debt$m32.9Long-term debt, Q3 FY2023, at 2023-09-30$32.9m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2023-11-09, accession 0001410578-23-002304.Report this figure40.8Long-term debt, FY2023, at 2023-12-31$40.8m. XBRL concept us-gaap:LongTermDebt. 10-K filed 2025-03-31, accession 0001410578-25-000598.Report this figure44.4Long-term debt, Q1 FY2024, at 2024-03-31$44.4m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-05-10, accession 0001410578-24-000741.Report this figure51.0Long-term debt, Q2 FY2024, at 2024-06-30$51.0m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-08-09, accession 0001410578-24-001278.Report this figure53.3Long-term debt, Q3 FY2024, at 2024-09-30$53.3m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-11-12, accession 0001410578-24-001879.Report this figure62.7Long-term debt, FY2024, at 2024-12-31$62.7m. XBRL concept us-gaap:LongTermDebt. 10-K filed 2026-04-15, accession 0001104659-26-043806.Report this figure64.1Long-term debt, Q1 FY2025, at 2025-03-31$64.1m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-05-15, accession 0001410578-25-001333.Report this figure64.7Long-term debt, Q2 FY2025, at 2025-06-30$64.7m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-08-14, accession 0001410578-25-001825.Report this figure72.2Long-term debt, Q3 FY2025, at 2025-09-30$72.2m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure60.0Long-term debt, FY2025, at 2025-12-31$60.0m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure59.4Long-term debt, Q1 FY2026, at 2026-03-31$59.4m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure52.0Long-term debt, Q2 FY2026, at 2026-06-30$52.0m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure
Current portion of debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Short-term borrowings$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m(70.1)Shareholders' equity, Q3 FY2023, at 2023-09-30−$70.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0001410578-24-001879.Report this figure(65.8)Shareholders' equity, FY2023, at 2023-12-31−$65.8m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-04-15, accession 0001104659-26-043806.Report this figure(73.3)Shareholders' equity, Q1 FY2024, at 2024-03-31−$73.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-14, accession 0001410578-25-001825.Report this figure(76.5)Shareholders' equity, Q2 FY2024, at 2024-06-30−$76.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure(80.1)Shareholders' equity, Q3 FY2024, at 2024-09-30−$80.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure(94.5)Shareholders' equity, FY2024, at 2024-12-31−$94.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure(99.5)Shareholders' equity, Q1 FY2025, at 2025-03-31−$99.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure(100)Shareholders' equity, Q2 FY2025, at 2025-06-30−$100.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure(109)Shareholders' equity, Q3 FY2025, at 2025-09-30−$108.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure(60.3)Shareholders' equity, FY2025, at 2025-12-31−$60.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure(50.5)Shareholders' equity, Q1 FY2026, at 2026-03-31−$50.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure(45.2)Shareholders' equity, Q2 FY2026, at 2026-06-30−$45.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure

Cash flow

Operating cash flow−$7.2m, Q2 FY2026
Capital expenditure$198.0k, Q2 FY2026
Northwest Biotherapeutics Inc, cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(13.9)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$13.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0001410578-24-001879. Derived: 9-month figure less the 6-month figure.Report this figure(17.0)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$17.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-31, accession 0001410578-25-000598. Derived: 12-month figure less the 9-month figure.Report this figure(12.4)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$12.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-15, accession 0001410578-25-001333.Report this figure(16.2)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$16.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-14, accession 0001410578-25-001825. Derived: 6-month figure less the 3-month figure.Report this figure(8.2)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$8.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001104659-25-112676. Derived: 9-month figure less the 6-month figure.Report this figure(20.2)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$20.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure(9.4)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$9.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure(6.7)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$6.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001104659-26-097188. Derived: 6-month figure less the 3-month figure.Report this figure(13.9)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$13.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001104659-25-112676. Derived: 9-month figure less the 6-month figure.Report this figure(14.8)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$14.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure(12.5)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$12.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure(7.2)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$7.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001104659-26-097188. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.4Capital expenditure, Q3 FY2023, three months to 2023-09-30$437.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-12, accession 0001410578-24-001879. Derived: 9-month figure less the 6-month figure.Report this figurenot reported0.2Capital expenditure, Q1 FY2024, three months to 2024-03-31$239.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-15, accession 0001410578-25-001333.Report this figure0.5Capital expenditure, Q2 FY2024, three months to 2024-06-30$521.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-14, accession 0001410578-25-001825. Derived: 6-month figure less the 3-month figure.Report this figure0.2Capital expenditure, Q3 FY2024, three months to 2024-09-30$176.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001104659-25-112676. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2024, three months to 2024-12-31$78.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2025, three months to 2025-03-31$93.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure0.3Capital expenditure, Q2 FY2025, three months to 2025-06-30$304.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-14, accession 0001104659-26-097188. Derived: 6-month figure less the 3-month figure.Report this figure0.2Capital expenditure, Q3 FY2025, three months to 2025-09-30$202.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001104659-25-112676. Derived: 9-month figure less the 6-month figure.Report this figure0.9Capital expenditure, Q4 FY2025, three months to 2025-12-31$905.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2026, three months to 2026-03-31$129.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure0.2Capital expenditure, Q2 FY2026, three months to 2026-06-30$198.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-14, accession 0001104659-26-097188. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)1.64bn, Q2 FY2026
Northwest Biotherapeutics Inc, shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares1.0Diluted shares (weighted), Q3 FY2022, three months to 2022-09-301,040,982 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0001410578-23-002304.Report this figure1.1Diluted shares (weighted), Q1 FY2023, three months to 2023-03-311,074,902 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-10, accession 0001410578-24-000741.Report this figure1.1Diluted shares (weighted), Q2 FY2023, three months to 2023-06-301,108,420 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-09, accession 0001410578-24-001278.Report this figure1.1Diluted shares (weighted), Q3 FY2023, three months to 2023-09-301,134,359 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0001410578-24-001879.Report this figure1.2Diluted shares (weighted), Q1 FY2024, three months to 2024-03-311,188,149 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-15, accession 0001410578-25-001333.Report this figure1.2Diluted shares (weighted), Q2 FY2024, three months to 2024-06-301,214,316 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-14, accession 0001410578-25-001825.Report this figure1.3Diluted shares (weighted), Q3 FY2024, three months to 2024-09-301,258,532 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure1,359Diluted shares (weighted), Q1 FY2025, three months to 2025-03-311,359,496,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure1,438Diluted shares (weighted), Q2 FY2025, three months to 2025-06-301,438,198,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure1.5Diluted shares (weighted), Q3 FY2025, three months to 2025-09-301,492,079 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure1,585Diluted shares (weighted), Q1 FY2026, three months to 2026-03-311,584,843,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure1,642Diluted shares (weighted), Q2 FY2026, three months to 2026-06-301,642,439,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure

Shares outstanding: 1.71bnShares outstanding, period not labelled, at 2026-08-131,705,637,993 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure at Aug 13, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. Listed shows no prices and gives no investment advice.